CITA Biomedical, Inc. (DTOX)

[jmhollen]

CITA Biomedical Names Chief Financial Officer
John Peters, 20-year Financial Veteran, Joins CITA Biomedical Management Team

BEVERLY HILLS, Calif., Oct. 22 /PRNewswire-FirstCall/ -- CITA Biomedical, Inc. (CITA) (OTC Bulletin Board: DTOX) a growing leader in the treatment of substance dependency, today named John Peters as the company's Chief Financial Officer (CFO).

Mr. Peters brings to CITA over 20 years experience in the financial community. Most recently, Mr. Peters was a co-founding partner and Chief Financial Officer of Trilennia Group LLC. Previously, he was the Vice President of Finance for AutoWeb, an online business-to-business trading exchange for the automotive industry. John also served as Chief Financial Officer for PNBC, a web based trade show registration services provider. Over a fifteen-year period with KPMG he provided strategic audit and consulting services to both publicly traded and privately held companies.

(Photo: http://www.newscom.com/cgi-bin/prnh/19990413/LAPHOTO )

"We are extremely pleased that someone of John's caliber will be joining CITA," said Steve Rutlen, president of CITA Biomedical. "His track record and experience in building companies and managing them through rapid growth are very appealing at this stage in our business plan. As we roll-out our new treatment family, DNA for Addictions and expand our delivery channels across the U.S. and Canada, John's experience will be invaluable."

"I'm pleased to be joining a company that is committed to delivering high quality, safe addiction treatments for its customers," said Mr. Peters. "I believe CITA is poised for significant growth, expansion, and believe they have the potential to become the addiction treatment market leader."

In his role as CFO, Mr. Peters will be responsible for all aspects of the financial organization for CITA Biomedical, Inc. and subsidiaries. His appointment is effective immediately.

About CITA Biomedical, Inc.

CITA Biomedical, Inc., headquartered in Beverly Hills, Calif., focuses on the innovative treatment of addiction. The company holds the U.S. patent for its successful UROD (Ultra Rapid Opiate Detoxification) treatment method. UROD is the only clinically tested and effective treatment method to rapidly detoxify individuals addicted to opiate-based drugs, including heroin within four to six hours with few, if any, withdrawal symptoms. The company has a new family of revolutionary treatments, Detoxification and NeuroAdaptation (DNA) for Addictions. The first treatments from this family treat alcohol, cocaine, crack, and poly-drug addictions. To date, CITA has grown its business through internal expansion and now seeks compatible, leading, and complementing technologies and acquisitions to enhance its corporate portfolio. CITA Biomedical, Inc. has two operating divisions CITA Americas, Inc., and AltTPro, Inc. For more information, please visit http://www.citabio.com

UROD is a registered trademark of CITA Biomedical, Inc.

SOURCE CITA Biomedical, Inc.

CONTACT: investors, Judy Ryon of CITA Biomedical, Inc., [phone],
[e-mail], or Treatment Information, [phone]

PRN Photo Desk, [phone] or [phone]/

Web site: http://www.citatreatment.com

Web site: http://www.citabio.com

.